Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild, Jean‐Jacques Grob, Лев Вадимович Демидов et al. · The Lancet · 2012
Cited by 2,989 works. doi:10.1016/s0140-6736(12)60868-x
Authors
- Axel Hauschild
- Jean‐Jacques Grob
- Лев Вадимович Демидов
- Thomas Jouary
- Ralf Gutzmer
- Michael J. Millward
- Piotr Lukasz Rutkowski
- Christian U. Blank
- Wilson H. Miller
- Eckhart Kaempgen
- Salvador Martín‐Algarra
- Bogusława Karaszewska
- Cornelia Mauch
- Vanna Chiarion‐Sileni
- Anne-Marie Martin
- Suzanne Swann
- Patricia Haney
- Beloo Mirakhur
- Mary E. Guckert
- Vicki L. Goodman
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- Mutations of the BRAF gene in human cancer
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Cancer statistics, 2012
- Distinct Sets of Genetic Alterations in Melanoma
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- GLOBOCAN 2008 v1.2, Cancer incidence and mortality world-wide : IARC Cancer Base No. 10